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Previous work has demonstrated that the human cytomegalovirus IE1-72 protein is able to bind to the N
terminus of p107, and IE1-72 alone is sufficient for alleviation of p107-mediated cell growth suppression.
However, the mechanism of this alleviation is unclear. Here, we show that IE1-72 can alleviate p107 inhibition
of cyclin E/cdk2 kinase activity. We cotransfected various IE1-72 and p107 constructs into C33A cells and
demonstrated that IE1-72 could activate the kinase activity of cyclin E/cdk2. Conversely, IE2-86 did not activate
this activity, suggesting that the interaction between p107 and IE1-72 and the subsequent kinase activation are
specific. By the use of a series of deletion and point mutants of IE1-72 and p107, we observed that a mutation
of the loop region of helix-loop-helix-turn-helix in exon 3 of IE1-72 as well as a mutation of the leucine zipper-2
region in exon 4 of IE1-72 abolished binding to p107. In addition, these two IE1-72 mutants did not alleviate
p107 inhibition of cyclin E/cdk2 kinase activity and also failed to alleviate p107 inhibition of the E2F-responsive
promoter. Meanwhile, deletion of the N-terminal aa 1 to 175 of p107 abolished both p107 binding with IE1-72
and p107 inhibition of cyclin E/cdk2 kinase activity. This result confirms that the N-terminus aa 1 to 175 region
of p107 is a common region where both IE1-72 protein and cyclin E/cdk2 bind. We propose a mechanism in
which binding of IE1-72 to p107 displaces cyclin E/cdk2 from p107. Once released from p107, cyclin E/cdk2 is
able to function as an active kinase.
Human cytomegalovirus (HCMV), a member of the beta-
herpesvirus family, rarely causes symptomatic disease in
healthy, immunocompetent individuals (19). However, it may
lead to severe illness in immunocompromised and immuno-
suppressed individuals. HCMV induces the synthesis of the
cellular proteins associated with DNA replication (2–4, 15, 37).
It has recently been demonstrated that infection of rat smooth
muscle cells with HCMV increases smooth muscle cell prolif-
eration and migration (45). These observations strongly sup-
port the notion that HCMV infection can alter cellular metab-
olism to generate an environment conducive to proliferation.
We are interested in determining if HCMV disrupts cell cycle
regulation through interactions of viral early-immediate gene
products with cell cycle-regulating proteins.
The HCMV immediate-early (IE) proteins, IE1-72 and IE2-
86, are nuclear proteins that play important roles in the regu-
lation of both viral and cellular gene expression. IE2-86 can
transactivate a number of viral and cellular promoters (dihy-
drofolate reductase and thymidine kinase genes, etc.) which
are associated with cell proliferation and DNA replication (2,
11, 14, 16, 20, 23, 26, 28). Expression of IE2-86 induces the
progression of quiescent cells into S phase and delays cell cycle
exit. Analogous to IE2-86, expression of IE1-72 protein can
induce several S-phase-associated genes, including dihydrofo-
late reductase and DNA polymerase  (15, 27, 37). In the
absence of p53, IE1-72 expression can also induce S phase and
delay cell cycle exit (7).
The cyclins are key cell cycle regulatory factors that are
controlled by a number of mechanisms, including their gene
expression, phosphorylation, subcellular localization, and deg-
radation, as well as activation of cyclin-dependent kinases
(cdk’s) (1, 32, 34). Cyclin E/cdk2 kinase activity can be acti-
vated by the immediate-early genes, IE1 and IE2, in HCMV-
infected cells (4, 21). Transactivation of the cyclin E promoter
by IE2 has been reported (4), but the mechanism for IE1
activation of cyclin E/cdk2 kinase activity in HCMV-infected
cells is still unclear.
Another class of proteins involved in regulating the cell cycle
includes the retinoblastoma tumor suppressor protein (pRb)
and its related proteins, p107 and 130. These pRb-related
proteins serve as cell growth suppressors and share a homol-
ogous sequence called the pocket domain, which can bind to
E2F, a protein known to promote proliferation (9, 36). pRb is
thought to bind to and inhibit the activity of E2F, preventing
cell entry into S phase (18, 39). p107 contains two independent
domains implicated in cell growth suppression. The p107
pocket domain is located at the C terminus and, like the pocket
domain of pRb, can bind to and inhibit the activity of E2F4,
causing cell growth arrest in the G1 phase of the cell cycle. The
other growth-suppression domain is located at the N terminus
of p107 and interacts with cyclin/cdk kinases. p107 forms com-
plexes with cyclin A/cdk2 or cyclin E/cdk2 to repress the activ-
ity of these kinases (46, 47). The interaction between p107 and
cyclins and cdk’s that results in inhibition of kinase activity has
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been demonstrated to be a way to regulate the cell cycle (6, 36,
40, 41, 46, 47). The formation of complexes between p107 and
cyclin/cdk kinases appears in a temporally defined manner.
The p107-cyclin E/cdk2 complex is seen in late G1 phase, and
the p107-cyclin A/cdk2 complex is seen later in S phase (24,
48).
Both IE1-72 and IE2-86 are able to bind to pRb family
proteins. IE2-86 binds to pRb (8, 13), while IE1-72 binds to
p107 (22, 30). The interaction between IE1-72 and p107 is
dependent on the N terminus of p107 and exons 2, 3, and 4 of
IE1-72 (22). Because the N terminus of p107 is necessary for
binding to IE1-72 as well as to cyclin E/cdk2, we hypothesized
that IE1-72 could disrupt the complex between p107 and cy-
clinE/cdk2. Thus, when HCMV infects cells and IE1-72 is
expressed, the subsequent interaction of IE1-72 with p107
frees cyclin E/cdk2. This allows cyclin E/cdk2 to become an
active kinase. To assess this hypothesis and to further define
the interacting domains binding between p107 and IE1-72, we
employed a series of deletion and point mutants of IE1-72 and
p107. In this communication, we demonstrate that the inter-
action of IE1-72 with p107 does indeed activate cyclin E/cdk2
kinase activity. The helix-loop-helix-turn-helix (HLHTH) do-
main in exon 3 and leucine zipper-2 (LZ-2) in exon 4 of IE1-72
are necessary for its binding to p107. In addition, amino acids
(aa) 1 to 175 of the N-terminal region of p107 are essential for
its binding to IE1-72.
MATERIALS AND METHODS
Cell culture and infection. Human tumor cell line C33A and 293 cells were
obtained from the American Type Culture Collection (Rockville, Md.) and
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (GIBCO BRL, Rockville, Md.) and penicillin-strepto-
mycin (100 U and 100 g/ml, respectively) at 37°C in a 6% CO2 incubator (30).
The transfections or cotransfections for immunoprecipitation (IP) and Western
analysis were performed as described in the Effectene transfection reagent hand-
book (Qiagen, Valencia, Calif.).
Preparation of cell lysates for Western analysis, IP, and kinase assays. Pro-
cedures for preparation of whole-cell lysates for Western blotting and IP were
performed as described previously (30). Cells were harvested at the indicated
times posttransfection. Cells were pelleted by low-speed centrifugation and
washed twice with phosphate-buffered saline (PBS). Cells were then incubated in
an EBC buffer (0.05 M Tris-HCl [pH 8.0], 0.12 M NaCl, 0.5% Nonidet P-40, 0.1
M NaF, 0.2 mM Na-orthovanadate, 1 mM phenylmethylsulfonyl fluoride
[PMSF], 10 g of leupeptin/ml, and 1 g of aprotinin/ml) at 4°C for 1 h, or in
0.2% Tween 20 lysis buffer (50 mM HEPES [pH 7.3], 150 mM NaCl, 2.5 mM
EGTA, 1 mM EDTA, 0.2% Tween 20, 1 mM dithiothreitol, 1 mM PMSF, 1 g
of aprotinin/ml, 1 mM sodium orthovanadate, 10 mM -glycerophosphate, and 1
mM NaF) at 4°C for 4 h. Microcentrifugation at 13,600  g for 15 min at 4°C was
used for clarification. Supernatant was removed, and protein concentrations
were determined with the Bio-Rad (Richmond, Calif.) protein assay kit.
To prepare whole-cell extracts for the kinase assays, cells were rinsed twice
with PBS prior to harvest. Cell pellets were washed with PBS once and resus-
pended in 0.2% Tween 20 lysis buffer and lysed for 4 h on ice. Cellular debris was
removed by centrifugation for 15 min at 13,600  g at 4°C. The supernatant was
recovered and stored at 70°C until use (10).
Transfection and CAT assays. C33A cells were transfected with various com-
binations of plasmids as indicated using the Effectene kit, following the manu-
facturer’s protocol (Qiagen). Cells were grown in six-well plates and transfected
when a density of 50% confluence was reached. A total of 0.8 g of DNA was
used in each transfection. The mixture of DNA and Effectene reagent was
suspended in 600 l of DMEM and added to the cells in 1 ml of DMEM-free
serum. The cells were incubated at 37°C and 6% CO2 for 24 h, and then 1 ml of
DMEM with 12% fetal bovine serum was added (30). After 24 h, cells were
harvested and chloramphenicol acetyltransferase (CAT) assays were performed,
as described previously (12).
Immunocomplex kinase assays. Immunocomplex kinase assays were per-
formed as described previously (10). Cyclin E kinase complexes were immuno-
precipitated from 200 g of total cell protein with anti-cyclin E mouse mono-
clonal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) for 4 h at 4°C and
collected on 15 l of protein A–Sepharose CL-4B beads (Amersham, Piscataway,
N.J.) overnight at 4°C. Immunoprecipitates were washed twice with lysis buffer
(0.2% Tween 20 lysis buffer) and twice with kinase buffer (50 mM HEPES [pH
7.3], 10 mM MgCl2). They were then resuspended in 15 l of kinase buffer
(containing 1 mM dithiothreitol, 1 mM sodium orthovanadate, 2.5 mM EGTA,
20 M ATP, 10 mM -glycerophosphate, and 1 mM NaF) with 1.5 g of histone
H1 substrate (Upstate, Lake Placid, N.Y.) and 5 Ci of [-32P]ATP (ICN, Irvine,
Calif.). The kinase reaction was allowed to proceed for 30 min at 30°C and was
stopped by the addition of 15 l of 2 sodium dodecyl sulfate (SDS) sample
buffer. Samples were boiled for 5 min and then separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE). Gels were vacuum dried, and phosphorylated
substrate was visualized by autoradiography.
IP. Cell extracts of 500 g of protein were first precleared with protein A– or
protein G–Sepharose CL-4B beads (Amersham) for 1 h at 4°C. Beads were spun
out, and then the precleared cell extract was incubated with appropriate antibody
for 4 h. The protein complexes were precipitated by incubation with protein A–
or G–Sepharose CL-4B beads overnight at 4°C. Precipitated complexes were
washed three times with 0.2% Tween 20 lysis buffer and then resuspended in 2
sample buffer and boiled for 3 min. Proteins were separated by SDS-PAGE and
analyzed by Western blotting.
In vitro protein interaction. All transcription-translation of proteins was done
with the Promega TnT-coupled reticulocyte lysate system (Promega, Madison,
Wis.) for [35S]methionine labeling. The manufacturer’s protocol was followed.
Proteins were translated individually and then mixed in the indicated combina-
tions for 1 h at 30°C. IPs were performed with 20 l of translated protein, 0.5 g
of antibody, and 25 l of protein G beads, in 0.3 ml of ELB buffer. The
reactions were allowed to proceed overnight, and the beads were washed five
times with ELB before boiling and separation by SDS-PAGE. The gels were
dried and exposed to Kodak X-ray film.
Western blotting (immunoblotting) analysis. Equal protein amounts of whole-
cell extracts (35 to 100 g, depending on the specific antigen to be tested) were
separated by SDS-PAGE gels and then transferred for 3 to 4 h to Immobilon-P
membranes (Millipore, Billerica, Mass.). Blots were blocked in 5% (wt/vol)
nonfat dry milk dissolved in PBS–0.1% Tween 20. Blots were probed with
primary antibody in PBS–0.1% Tween 20 (1:1,000 dilution for anti-p107 [Santa
Cruz Biotechnology], 1:20,000 for anti-IE1-72 [our lab], 1:20,000 for anti-IE2-86
[our lab], and 1:1,000 for anti-cyclin E and anti-cdk2 antibody [Santa Cruz
Biotechnology]). After extensive washing, blots were probed with an appropriate
peroxidase-labeled secondary antibody. Blots were again washed extensively and
developed by enhanced chemiluminescence (ECL; Amersham).
Plasmid constructs. The IE1-72 and IE2-86 expression vectors
(pcDNA3IE1-72 and pcDNA3IE2-86) have been previously described (43). The
adenovirus E2CAT and the E2CAT mutant were gifts from Steve Bachenheimer
and were described previously (25). The p107 expression vector (pCMV-
neop107) and the p107 vector used for transcription-translation (pBSKII p107)
were obtained from Liang Zhu (46–48). pGEX2Tp107 used to produce gluta-
thione S-transferase (GST)-p107 was generated from pBSKp107 by inserting a
BamH1 fragment of p107 into pGEX2T at the BamH1 site. The direction of the
insertion was identified by DNA sequencing.
Construction of IE1-72 mutants. The cDNA fragment encoding IE1-72 in
pGEX2TIE1-72 was mutated by using the GeneEditor in vitro site-directed
mutagenesis system (Promega) and subcloned into pcDNA3 plasmid at the
BamH1 site. The site-directed mutants of IE1-72 were created using primers with
the following sequences: M10 (179-184), 5pGCATGATGTGAGCGAGGCCG
CCGCTACCGAGTTGGGGGGTGC; M11 (192-197), 5pGCACTGCAGGCT
ACGGCCCGTGCTACAACGGATGAACTTAGG; M12 (10-16), 5pCCAAG
AGAAGAGTGGCCCCTGCTAATCCTGCCGCGGGCCCTTCCTCC; M13-1
(45-52), 5pGTTGAGGAAGGAGGTTACCAGTCCGCTGAGTCTGGCAGC
CCCGCTGTTTCAGAG; M13-2 (71-77), 5pCTTTTGAACAAGTGACCGCG
GCTTCCACCGCGAAACCCGAGAAAGATGTCC; M13-3 (57-64), 5pGAC
CCGCTGTTTCCAGCGTTGGCCGCAGCATCCCTCACAACTTTTGAACA
AGTG; M14 (106-114), 5pCAAGGAGCACATGCTGACAACATCTACCCA
GACGGCAGCGCAATTCACTGGCGCCTTTAATATG; and M15 (312-318),
5pGAGTTCTGTCGGGTGCAGTCCTCCTCTGTCTTTGCGGAGACTAGT
GTGATGC. The cDNAs and the orientation of IE1-72 or its mutants in vectors
were verified by DNA sequencing. DNA and amino acid sequences and the
schematic location of the point mutants of IE1-72 are shown in Table 1 and
below in Fig. 4A, respectively.
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Construction of p107 deletions and mutants. The GeneEditor site-directed
mutagenesis kit (Promega) was used to create mutants of p107. The pCMVneop107
plasmid was used as a template DNA. The DNA sequences of primers used for
generating the p107 point mutants were as follows: p107M151 (151-156), 5pGAT
ATATTTCAAAATCCATCTAAAAAACCACAAACGTTACCACGAAGCCG;
p107M201 (201-208), 5pCTCTTATCATTTTTTTCTAAGCAGCTTTGCTCTGA
TTTTGCC; p107M291 (291-297), 5pGAGAATGCCTCCTGGCCCATCCAA-
GATATACTGCTAATAGCAAAGCAG; and p107M323 (323-329), 5pGAGGA
TCTTTTTGGAAGGAGCCGCAGCAGGGGCAATTGGAACACCTCG. These
constructed mutants were then used to create the constructs pcDNA3p107M151-
flag, pcDNA3p107M201-flag, pcDNA3p107M291-flag, and pcDNA3p107M323-flag
by ligating PCR products of C-terminal flag-tagged p107 mutant fragments flanked
with BamHI and XbaI sites into BamHI and XbaI cloning sites of the pcDNA3
plasmid. The following common primers were used: 5 primer, CATCGGATCCA
TGTTCGAGGACAAGCCCCAC; 3 primer, GCTCTAGATTACTTGTCGTCG
TCATCCTTGTAGTCATGATTTGCTCTTTCACTG. pcDNA3p107-flag was cre-
ated by a similar strategy.
Deletions of p107N30-flag and p107N175-flag, in which the first 30 or 175 aa
of p107 were deleted and the flag sequence was tagged at the C terminus of the
deletion, were produced by a similar strategy to that mentioned above, but the
template DNA was pCMVneop107 and the 5 primers were p107N30-flag (5C
ACTGGATCCATGGACGAGGGGAGCGCG) and p107N175-flag (5CGGC
GGATCCATGTTCTGTTGGACACTTTTTG). The common 3 primer men-
tioned above was used. DNA and amino acid sequences and the schematic of the
p107 deletion and point mutants are shown in Table 2 and also below in Fig. 8A.
RESULTS
Cyclin E/cdk2 kinase activity is inhibited by p107 overex-
pression but is activated by IE1-72 overexpression. To deter-
mine whether IE1-72 activates cyclin E/cdk2 kinase activity,
lysates of the C33A cells transfected with p107 or IE1-72 or
IE2-86 expression vector were immunoprecipitated with anti-
cyclin E antibody, anti-p107 antibody, anti-IE1 antibody, or
anti-IE2 antibody. The various IP complexes were tested in
kinase assays for the ability to phosphorylate histone H1. Ki-
nase activity in complexes immunoprecipitated with anti-cyclin
E antibody was inhibited by p107 overexpression (Fig. 1B, lane
2), but it was increased by IE1-72 overexpression (Fig. 1B, lane
4). Complexes immunoprecipitated from cell lysate by anti-
p107, anti-IE1-72, or anti-IE2-86 antibodies (Fig. 1B, lanes 3,
5, and 6) had little or no kinase activity, suggesting that either
cyclinE/cdk2 did not complex with these proteins or that cyclin
E/cdk2 in complexes with these proteins lacked kinase activity.
Coexpression of p107 and IE1-72 resulted in cyclin E/cdk2
kinase activity, and kinase activity increased with increased
expression of IE1-72. Cotransfection of p107 and IE1-72 ex-
pression constructs into the C33A cell line was performed, and
lysates of these cells were prepared. Cyclin E/cdk2 complexes
were immunoprecipitated by anti-cyclin E antibody from these
lysates, and the kinase activities of the IP complexes were
examined (Fig. 2). p107 overexpression alone inhibited histone
H1 phosphorylation catalyzed by cyclin E/cdk2 (Fig. 2, lane 2).
However, IE1-72 coexpression resulted in restoration of cyclin
E/cdk2 kinase activity (Fig. 2, lanes 3 to 5), and this kinase
activity increased with increased IE1-72 protein expression
(Fig. 2, lanes 3 to 5). It was reported previously that the cyclin
TABLE 1. Mutated sequences of the IE1–72 protein
Mutant DNA sequence change Amino acid sequence change
M10 (179-184) (Mut ATP binding) From AAGGGCGCCGCTAACAAG KGAANK
To GAGGCCGCCGCTACCGAG EAAATA
M11 (192-197) (Mut NL-2) From AAGGCCCGTGCTAAAAAG KARAKK
To ACGGCCCGTGCTACAACG TARATT
M12 (10-16) (Mut exon 2) From GACCCTGATAATCCTGACGAG DPDNPDE
To GCCCCTGCTAATCCTGCCGCG APANPAA
M13-1 (45-52) (Mut exon 3 loop) From AACAGTCAGCTGAGTCTGGGAGAC NSQLSLGD
To ACCAGTCCGCTGAGTCTGGCAGCC TSPLSLAA
M13-2 (71-77) (Mut exon 3 turn) From GAGGATTGCAACGAGAACCCC EDCNENP
To GCGGCTTCCACCGCGAAACCC AASTAKP
M13-3 (57-64) (Mut exon 3 helix) From GAGTTGGCCGAAGAATCCCTCAAA ELAEESLK
To GCGTTGGCCGCAGCATCCCTCACA ALAAASLT
M14 (106-114) (Mut NL-1) From AAAAAATATACCCAGACGGAAGAGAAA KKYTQTEEK
To ACAACATCTACCCAGACGGCAGCGCAA TTSTQTAAQ
M15 (312-318) (Mut LZ-2) From CTGTGCTGCTATGTCTTAGAG LCCYVLE
To CAGTCCTCCTCTGTCTTTGCG QSSSVFA
TABLE 2. Sequences of p107 mutants
Mutant name DNA sequence change Amino acid sequence change
p107N30 (del.1-30) Bases 1–90 deleted aa residues 1–30 deleted
p107N175 (del. 1-175) Bases 1–525 deleted aa residues 1–175 deleted
p107M151 (151-156) From TATGAAGAACCACCAAAG YEEPPK
To TCTAAAAAACCACAAACG SKKPQT
p107M201 (201-208) From TTACTTCTATGCTGCTTGGAT LLLCCLDL
To TTTTTTCTAAGCAGCTTTGCT FFLSSFAL
p107M291 (291-297) From GACCTTTCAAGTTTTACTGAT DLSSFTD
To GCCCATCCAAGATATACTGCT AHPNYTA
p107M323 (323-329) From GGAGCAGACGCAGAAGAGGAA GADAEEE
To GAAGGAGCCGCAGCAGGGGCA EKAAAKA
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E promoter was activated by HCMV IE2-86 expression (4).
Therefore, the kinase activity from pcDNA3IE2-86- and
pCMVp107-transfected C33A cell lysate was used as a positive
control in this experiment. In lane 7 of Fig. 2, an increase in
cyclin E/cdk2 kinase activity induced by IE2-86 was observed.
This kinase activity was mainly due to IE2-86 up-regulation of
the cyclin E promoter and not from the release of cyclin E/cdk2
from the p107-cyclin E/cdk2 inactive complex. This result sug-
gests that either the interaction of p107 with IE1-72 or an
up-regulation of cyclin E/cdk2 by IE1-72 alone may contribute
to the increase of cyclin E/cdk2 kinase activity. However, we
found IE1-72 and p107 expression alone or together in C33A
cells did not significantly increase endogenous cyclin E and
cdk2 expression, as shown below in lanes 2, 3, and 12 of Fig.
5A.
IP complexes containing p107 showed kinase activity when
mixed with IP complexes containing IE1-72, and kinase activ-
ity increased with increasing levels of IE1-72. We hypothesized
that IE1-72 binding to p107 displaces cyclin E/cdk2 from the
p107-cyclin E/cdk2 complex, thereby activating the cyclin
E/cdk2 kinase activity. To test this hypothesis, p107, IE1-72,
and IE2-86 expression constructs were transfected into C33A
cells. Protein complexes were immunoprecipitated from cell
lysates using either anti-p107 antibody or anti-cyclin E anti-
body. These IP complexes were then mixed with IP complexes
immunoprecipitated with either anti-IE1-72 antibody or anti-
IE2-86 antibody. Finally, the kinase activity of the mixed IP
complexes was analyzed for histone H1 phosphorylation. Anti-
p107 antibody IP complexes immunoprecipitated from cells
transfected with pcDNA3 p107 mixed with anti-IE1-72 IP com-
plexes immunoprecipitated from cells transfected with
pcDNA3 (expression vector alone) had minimal kinase activity
(Fig. 3C, lane 1). However, anti-p107 antibody IP complexes
from the cells transfected with 2 g of pcDNA3p107 mixed
with anti-IE1-72 antibody IP complexes from cells transfected
with 2 g of pcDNA3IE1-72 showed kinase activity (Fig. 3C,
lane 4). The level of kinase activity in the mixed IP complexes
increased with the level of IE1-72 expression (Fig. 3C, lanes 2
to 4). Anti-p107 antibody IP complexes from the cells trans-
fected with 2 g of pcDNA3 p107 mixed with anti-IE2-86
antibody IP complexes from cells transfected with
pcDNA3IE2-86 showed no kinase activity (Fig. 3C, lane 5).
The HLHTH and LZ-2 regions of IE1-72 are required for
interaction with p107 in vitro. In order to define the domains
of the IE1-72 protein that interact with p107, eight point mu-
tants of the IE1-72 gene were constructed (Table 1 and Fig.
4A) and expressed in an in vitro transcription-translation sys-
tem containing [35S]methionine. The [35S]methionine-labeled
gene products were analyzed for construct expression by SDS-
PAGE and autoradiography (Fig. 4B). [35S]methionine-la-
beled full-length IE1-72 or one of the eight mutant products
was mixed with [35S]methionine-labeled p107, and IE1-72 pro-
tein complexes were immunoprecipitated from these mixtures
with anti-IE1-72 antibody. The IP complexes were analyzed for
the presence of p107 with SDS-PAGE and autoradiography.
[35S]methionine-labeled p107 coimmunoprecipitated with full-
length IE1-72 and IE1 mutants M10, M11, M12, M13-2,
M13-3, and M14 (Fig. 4C, lanes 4–6, 7, and 9–11), but not with
M13-1 or M15 (Fig. 4C, lanes 8 and 12). We noticed that in the
coimmunoprecipitation of the in vitro-translated M13-1 mu-
tant protein and of p107 using anti-IE1-72 antibody, the M13-1
protein level was less than that of the other mutants (Fig. 4C,
lane 8). We do not understand the reason for this at this
moment, but it is reproducible and the results are quite con-
sistent. Although the M13-1 protein level is relatively low, no
trace amount of coprecipitated p107 was detected. The IE1-72
antibody used for IP was a monoclonal antibody. It may have
less affinity to the M13-1 mutant protein than to the wild type
and other mutant proteins, but it is still very immunoreactive
FIG. 1. Overexpressed p107 inhibited cyclin E/cdk2 kinase activity,
while overexpressed IE1-72 activated cyclin E/cdk2 kinase. (A) West-
ern blot analyses demonstrating expression levels of p107, IE1-72, and
IE2-86 in C33A cells transfected with the indicated constructs. (B) Ki-
nase assays of complexes immunoprecipitated with anti-cyclin E anti-
body from mock-transfected C33A cells (lane 1), cells overexpressing
p107 (lane 2), and cells overexpressing IE1-72 (lane 4). Lanes 3, 5, and
6 show kinase assays of complexes immunoprecipitated with anti-p107,
anti-IE1-72, or anti-IE2-86 antibodies, respectively. His.H1, histone
H1.
FIG. 2. p107 overexpression inhibited histone H1 phosphorylation
catalyzed by cyclin E/cdks, and IE1-72 expression reversed this inhib-
itory effect. (A) Western blot analyses demonstrating expression of
p107, IE1-72, and IE2-86 in C33A cells transfected with the indicated
constructs. (B) Kinase assays of complexes immunoprecipitated with
anti-cyclin E antibody from lysates of mock-transfected cells (lane 1),
cells transfected with p107 plasmid alone (lane 2), cells cotransfected
with p107 plasmid and increasing amounts of IE1-72 plasmid (lanes 3
to 5), or cells cotransfected with p107 plasmid and IE2-86 plasmid
(lane 7).
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against the M13-1 protein (see Fig. 5A and B, 6B, and 7B) as
detected by immunoblotting. To confirm that the M13-1 mu-
tant protein does not interact with p107, we performed a GST-
p107 pull-down experiment using in vitro-translated and
[35S]methionine-labeled IE1-72 proteins. The results demon-
strated that neither the M13-1 nor the M-15 mutant bound to
GST-p107 (Fig. 4D, lanes 6 and 10, respectively). This result
agrees with the result shown in Fig. 4C.
Mutation 13-1 is located in the helix-loop-helix region of
exon 3 (aa 45 to 52, with a sequence of NSQLSLGD), and
mutation 15 is located in the LZ-2 region of exon 4 (aa 312 to
318; LCCYVLE). To examine whether the binding was spe-
cific, [35S]methionine-labeled IE2-86 was used as a control.
IE2-86 did not bind to p107 (Fig. 4C, lane 13). The anti-IE1-72
antibody reacted to IE1-72 but not to p107 (Fig. 4C, lanes 3
and 2).
HLHTH and LZ-2 regions of IE1-72 are required for bind-
ing to p107 and induction of cyclin E/cdk2 kinase activity in
vivo, and mutations in these regions inhibit IE1-72 activation
FIG. 3. IP complexes containing p107 showed kinase activity when
mixed with IP complexes containing IE1-72, and kinase activity in-
creased with increasing levels of IE1-72. (A and B) Western blot
analyses demonstrating p107, IE1-72, and IE2-86 expression in C33A
cells transfected with the indicated expression vectors. (C) Kinase
assays of mixtures of various IP complexes. Lanes 1 to 4, complexes
immunoprecipitated with anti-p107 antibody from cells overexpressing
p107 (see panel A, lanes 1 to 4) mixed with complexes immunopre-
cipitated with anti-IE1-72 antibody from mock-transfected cells (see
panel B, lane 1) or cells transfected with increasing amounts of IE1-72
plasmids (see panel B, lanes 2 to 4). Lane 5, complexes immunopre-
cipitated with anti-p107 antibody from cells overexpressing p107 (see
panel A, lane 5) mixed with complexes immunoprecipitated with anti-
IE1-86 antibody from cells transfected with IE2-86 plasmid (see panel
B, lane 5). Lane 6, complexes immunoprecipitated with anti-cyclin E
antibody from cells overexpressing IE1-72 (see panel A, lane 6) mixed
with complexes immunoprecipitated with anti-IE1-72 antibody from
mock-transfected cells (see panel B, lane 6).
FIG. 4. The aa 45 to 52 (loop structure of HLHTH) and aa 312 to
318 (LZ-2) sequences of IE1-72 are required for its interaction with
p107. (A) Schematic diagram of the mutation sites of constructed
IE1-72 mutants. (B) Autoradiographs of direct loads of in vitro-trans-
lated [35S]methionine-labeled p107, IE1-72, IE1-72 mutant proteins,
and IE2-86, as indicated. (C) Autoradiographs of [35S]methionine-
labeled proteins within complexes immunoprecipitated with various
antibodies. Lane 1, [35S]methionine-labeled p107 protein immunopre-
cipitated with anti-p107 antibody; lane 2, [35S]methionine-labeled p107
protein immunoprecipitated with anti-IE1-72 antibody; lane 3,
[35S]methionine-labeled IE1-72 immunoprecipitated with anti-IE1-72
antibody; lanes 4 to 12, [35S]methionine-labeled IE1-72 (wild type and
mutants) and p107 within complexes immunoprecipitated with anti-
IE1-72 antibody; lanes 13 to 15, [35S]methionine-labeled proteins in
complexes immunoprecipitated with anti-IE2-86 antibody (controls).
(D) GST-p107 pull-down experiment using in vitro-translated and
[35S]methionine-labeled IE1-72 wild-type or mutant proteins. Results
demonstrated that M13-1 and the M-15 mutant did not bind to GST-
p107.
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of p107-cyclin E/cdk2 complex kinase activity. To determine if
mutations in the HLHTH and LZ-2 regions of IE1-72 would
affect binding to p107 in vivo, the eight mutant IE1-72 con-
structs were cotransfected with pCMVp107 into C33A cells.
Protein expression profiles were confirmed by Western blotting
(Fig. 5A). Complexes were immunoprecipitated from cell ly-
sates using anti-p107 antibody and analyzed by Western blot-
ting using anti-IE1-72 antibody to detect coimmunoprecipi-
tated IE1-72 or IE1-72 mutants (Fig. 5B). IE1-72 mutant
proteins M13-1 and M15 did not coimmunoprecipitate with
p107 (Fig. 5B, lanes 7 and 11, respectively). The kinase activity
of the IP complexes immunoprecipitated with anti-cyclin E
antibody from these lysates was determined (Fig. 5C). IP com-
plexes from cells expressing IE1-72 mutants M13-1 and M15
showed no cyclin E/cdk2 kinase activity (Fig. 5C, lanes 7 and
11). Kinase activity was seen in IP complexes from cells ex-
pressing full-length IE1-72 as well as those cells expressing
IE1-72 mutants M10, M11, M12, M13-2, M13-3, and M14 (Fig.
5C, lanes 3, 4, 5, 6, 8, 9, and 10, respectively).
To confirm which domains of IE1-72 are essential for acti-
vating the cyclin E/cdk2 kinase activity of the p107-cyclin
E/cdk2 complex, p107, full-length IE1-72, and IE1-72 mutant
constructs were transfected into C33A cells. In a protocol
similar to that described for Fig. 3, anti-p107 antibody IP
complexes were immunoprecipitated from cells transfected
with pCMVp107 and mixed with anti-IE1-72 antibody IP com-
plexes immunoprecipitated from cells expressing IE1-72 con-
structs. The IP complex mixtures were screened for kinase
activity (Fig. 6C). As expected, IP complexes from cells ex-
pressing full-length IE1-72 induced kinase activity (Fig. 6C,
lane 2). In addition, IP complexes from cells expressing IE1-72
mutants M10, M11, M12, M13-2, M13-3, and M14 also in-
duced kinase activity. Conversely, IP complexes from cells ex-
pressing mutants M13-1 or M15 did not induce kinase activity
(Fig. 6C, lanes 6 and 10). As seen in Fig. 6C, lane 11, IE1-72
expression alone in C33A cells led to very high kinase activity,
suggesting a very high level of active cyclin E/cdk2 kinase.
IE1-72 expression alleviates p107-medated repression of the
E2FCAT promoter, and mutations of the HLHTH and LZ-2
regions of IE1-72 abolish this alleviation. We have previously
reported that IE1-72 alleviates p107-mediated repression of
the E2F-responsive promoter (22, 30). To determine the do-
mains of IE1-72 necessary for this function, C33A cells were
transfected with E2FCAT, a reporter gene containing an E2F-
responsive promoter, as well as with p107 and various IE1-72
constructs. Lysates from these cells were assayed for CAT
activity. p107 overexpression inhibited E2FCAT expression
(Fig. 7A, lane 6), but E2FCAT expression increased with in-
creased IE1-72 expression (Fig. 7A, lanes 7 and 8).
CAT activity was also seen in cells cotransfected with IE1-72
mutants M10, M11, M12, M13-2, M13-3, and M14 (Fig. 7B,
lanes 5, 6, 7, 9, 10, and 11, respectively). However, cells co-
transfected with IE1-72 mutants 13-1 and 15 did not alleviate
p107-mediated repression of the E2FCAT gene (Fig. 7B, lanes
8 and 12). The fold differences for the CAT assays in Fig. 7 are
small (three to sixfold), but they are significant and consistent.
FIG. 5. aa 45 to 52 and 312 to 318 of IE1-72 are required for
binding to p107 and for alleviating p107 repression of cyclin E/cdk
kinase activity. (A) Western blotting showing expression of cyclin E,
cdk2, p107, IE1-72, and IE1-72 mutant proteins expressed in C33A
cells cotransfected with the indicated plasmid constructs. Note that
cyclin E and cdk2 are endogenous proteins (lane 1). (B) Western blots
demonstrating anti-IE1-72 immunoreactivity in complexes immuno-
precipitated with anti-p107 antibody from cell lysates of the same
transfected cells as in panel A. (C) Histone H1 kinase assays using
immune complexes immunoprecipitated with anti-cyclin E antibody
using cellular lysates as described in the legend for panel A.
FIG. 6. aa 45 to 52 and 312 to 318 of IE1-72 are necessary for
activating cyclin E/cdk kinase activity. (A) Western blotting demon-
strating expression of p107 or IE1-72 in lysates of C33A cells trans-
fected with pCMV p107 (lanes 1 to 10) or pcDNA3 IE1-72 (lane 11).
These lysates were subsequently immunoprecipitated with anti-p107
antibody or anti-cyclin E antibody (as indicated at the bottom of the
panel), and the IP complexes were mixed with IP complexes repre-
sented in the corresponding lanes of panel B and assayed for kinase
activity, as shown in panel C. (B) Western blot demonstrating IE1-72
or mutants of IE1-72 in lysates of C33A cells transfected by the indi-
cated constructs. These lysates were subsequently immunoprecipitated
with anti-IE1-72 antibody, and the IP complexes were mixed with IP
complexes represented in the corresponding lanes of panel A and
assayed for kinase activity, as shown in panel C. (C) Histone H1 kinase
assays of mixed IP complexes (see panels A and B).
VOL. 77, 2003 INTERACTION DOMAINS OF HCMV IE1-72 AND p107 12665
These results suggest that the HLHTL and LZ-2 regions of the
IE1-72 protein are essential for the alleviation of p107-medi-
ated suppression of the E2F-responsive CAT reporter.
Deletion of aa 1 to 175 of p107 abolishes p107 binding to
IE1-72 in vivo and abolishes inhibition of cyclin E/cdk2 kinase
activity in vitro. To further map the domains at the N terminus
of p107 that interact with the IE1-72 protein, we constructed a
series of deletion and point mutants of p107 located at the N
terminus of p107 (Table 2). The deletion and point mutants of
p107 and full-length IE1-72 plasmids were expressed in an in
vitro transcription-translation system with [35S]methionine.
The [35S]methionine-labeled mutants of p107 were mixed with
[35S]methionine-labeled IE1-72. The mixture was immunopre-
cipitated with anti-IE1-72 antibody. The IP complexes were
separated by SDS-PAGE for autoradiography. Of the various
p107 mutants, only p107N175 did not coimmunoprecipitate
with IE1-72 (Fig. 8C, lane 6). This mutant protein lacked aa 1
to 175.
To further confirm this result, either pcDNA3p107-f or
pcDNA3p107N175-f (f denotes the presence of a flag tag) was
cotransfected with pcDNA3IE1-72 into C33A or 293 cells. Cell
lysates were immunoprecipitated with anti-flag antibody, and
the IP products were screened by Western blotting using anti-
IE1-72 antibody. IE1-72 did not coimmunoprecipitate with the
p107N175 deletion mutant (Fig. 9A, lane 3). Functionally, the
p107N175 mutant did not inhibit cyclin/cdk kinase activity in
C33A cells transfected with the mutant construct (Fig. 9B, lane
3).
IE1-72 displaces cyclin E/cdk2 from the p107-cyclin E/cdk2
complex. It has been demonstrated that p107 forms a complex
with cyclin E/cdk2 (35, 36), and the N terminus of p107 is
required for this complex formation (35, 36). The physical
interaction of this complex formation is thought to be the
mechanism behind cyclin E/cdk2 kinase inactivation. We have
FIG. 7. IE1-72 coexpression with p107 alleviates p107-mediated
repression of the E2FCAT promoter, and aa 45 to 52 and 312 to 318
of the IE1-72 protein are essential for alleviating p107-mediated sup-
pression of the E2F-responsive CAT reporter construct. (A) Western
blot showing expression of p107 and IE1-72 in C33A cells cotrans-
fected with the indicated expression plasmids (upper panel). E2FCAT
that contains an E2F-responsive promoter was subsequently used as a
reporter gene to study the effect of IE1-72 on p107-mediated repres-
sion of the E2F-responsive gene. The results of CAT expression assays
of lysates from cells transfected with various IE2-72 mutants are shown
in the lower panel. (B) Western blots showing expression of p107 and
IE1-72 in C33A cells cotransfected with the indicated expression plas-
mids (upper panel). The lower panel shows CAT expression assays of
lysates from cells represented in the upper panel.
FIG. 8. The aa 1 to 175 sequence of the p107 protein is required for
interaction with the IE1-72 full-length protein. (A) Schematic diagram
showing the mutation sites of various p107 mutants. (B) Autoradio-
graph of direct loads of in vitro-translated [35S]methionine-labeled
IE1-72 and mutants of p107, as indicated. (C) Autoradiographs show-
ing the presence of [35S]methionine-labeled IE1-72 and/or p107 or
p107 mutant proteins in IP complexes from mixtures of the proteins, as
indicated, immunoprecipitated with anti-IE1-72 monoclonal antibody
(lanes 2 to 10) or with anti-p107 antibody (lane 1).
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now demonstrated that this region is also required for binding
to IE1-72. Since IE1-72 appears to activate kinase activity, we
hypothesized that IE1-72 binding to p107 physically displaces
cyclin E/cdk2. To assess this hypothesis, we used wild-type
p107 and p107 mutants, each flag tagged at the C-terminal end
to determine the displacement domain of p107 that interacts
with IE1-72. Unfortunately, for unclear reasons, we had rela-
tively poor expression of p107-f in plasmid-transfected C33A
cells. As higher levels of expression were needed, we then
utilized the transformed primary human embryonic kidney cell
line, 293, to overexpress the various flag-tagged p107 con-
structs. The expressed p107-f and flag-tagged mutants were
then used to perform protein displacement studies.
293 cells were cotransfected with various combinations of
plasmids encoding p107-f, p107N175-f, IE1-72, and IE1-86
(Fig. 10A). IP complexes using anti-flag antibody were pro-
duced from cell lysates, and these complexes were probed for
the presence of cyclin E, cdk2, and IE1-72. Cyclin E and cdk2
coimmunoprecipitated with p107-f in cells expressing p107-f
alone (Fig. 10A and B, lane 1) as well as in cells coexpressing
p107-f and IE2-86 (Fig. 10A and B, lane 3). Neither cyclin E
nor cdk2 was present in complexes from cells coexpressing
p107-f and IE1-72 (Fig. 10A and B, lane 2), but IE1-72 was
seen in these complexes (Fig. 10C, lane 2). Neither cyclin E,
cdk2, nor IE1-72 coimmunoprecipitated with the deletion mu-
tant protein p107N175-f (Fig. 10, lanes 4 and 5).
DISCUSSION
In eukaryotes, cell growth and differentiation are governed
through cell cycle progression, which is regulated by cell cycle-
related proteins that act either to promote or restrain cell
growth. The retinoblastoma family of proteins, which consists
of pRb, p107, and p130, are well-studied growth suppression
proteins that restrain cell growth by negatively regulating the
E2F transcription factor and cyclin/cdk kinase activity (40, 46).
On the other hand, cell cycle progression is positively regulated
by cyclin/cdk kinases that drive cell cycle progression by phos-
phorylating substrates such as the pRb family of proteins (40).
Distinct phases of the cell cycle are controlled by specific cdk’s
that complex with their respective catalytic subunit cyclins.
cdk4 and cdk6 complexed with cyclin D1 are responsible for
cell cycle progression through G1 (49), while cyclin E/cdk2
functions in the progression of the cell cycle from late G1 to
early S phase (33).
In general, pRb plays a critical role in G1-S checkpoint
control, whereby unphosphorylated pRb prevents cellular pro-
liferation by binding with E2Fs and inhibiting cell cycle pro-
gression (29, 38). Phosphorylation of pRb by cyclin/cdk com-
FIG. 9. aa 1 to 175 of p107 is required for interaction with IE1-72 in plasmid-transfected 293 cells, and the aa 1 to 175 fragment of p107 is
essential for inhibiting cyclin E/cdk2 kinase activity. (A) Western blots showing expression of IE1-72, p107-f, and p107N175-f in 293 cells
transfected with the indicated plasmids (upper panel). The bottom panel shows the presence or absence of IE1-72 by Western blot analysis of IP
complexes immunoprecipitated with anti-flag antibody from lysates of the cells represented in the upper panel. Note that IE1-72 did not
coimmunoprecipitate with the p107N175-f mutant (lane 3). (B) Western blot confirming expression of p107-f or p107N175-f in C33A cells
transfected with the indicated plasmids (upper panel). Kinase activity of IP complexes immunoprecipitated from cell lysates with anti-cyclin E
antibody is shown in the lower panel.
FIG. 10. p107-f coimmunoprecipitates with cyclin E and cdk2, and
IE1-72 disrupts the interaction. (A) Western blot showing cyclin E
immunoreactivity in IP complexes immunoprecipitated with anti-flag
antibody from lysates of cells transfected with the indicated plasmid.
(B) cdk2 immunoreactivity in the IP complexes described in panel A.
(C) IE1-72 immunoreactivity in the IP complexes shown in panel A.
VOL. 77, 2003 INTERACTION DOMAINS OF HCMV IE1-72 AND p107 12667
plexes results in the release of active E2F species to stimulate
the transcription of genes involved in DNA synthesis and S-
phase progression (17, 31). Data from our laboratory and from
others has demonstrated that infection by HCMV is capable of
activating cellular DNA replication machinery and driving qui-
escent cells to enter an S-phase-like environment (2, 11, 14,
37). HCMV activation of the cellular proliferation machinery
is attributed to two major mechanisms: (i) viral ligand and
cellular receptor interactions trigger viral signaling to activate
important cellular transcription factors, such as Sp1 and
NF-	B (42–44), and (ii) the expression of promiscuous, trans-
activating IE1-72 and IE2-86 proteins that are able to disrupt
cell cycle regulation through their interaction with pRb family
proteins (13, 22, 30).
A common paradigm for the creation of a cellular environ-
ment favorable to virus DNA replication, established by the
study of the small DNA tumor virus, is that only one of each
virally encoded protein (E1A of adenovirus, E7 of human
papillomavirus, and large T of simian virus 40) binds to all
members of the pocket domain proteins—pRb, p107, and
p130—and alleviates transcriptional repression by these pro-
teins. However, data from our laboratory and from others have
shown that two HCMV IE gene products, IE1-72 and IE2-86,
interact specifically with different pocket proteins. HCMV IE1-
72, but not IE2-86, complexes with cellular p107 during
HCMV infection, while IE2-86 binds to pRb (13, 22, 30). The
binding of IE1-72 to p107 was specific and did not extend to an
interaction with the closely related pRb protein. These results
suggest that HCMV might have a different mechanism for
temporally regulating the pocket domain proteins to create a
cellular environment favorable for viral DNA replication.
IE2-86 binding to pRb resulted in the release of E2F from
the pRb-E2F complex, but the IE1-72 interaction with p107,
although sufficient to functionally activate E2F-mediated tran-
scription, did not release E2F from the p107-E2F complex
(22). In addition, the N385 mutant of p107, which lacks the
N-terminal aa 1 to 385 fragment that binds to the cyclin/cdk2
complex to inhibit its kinase activity, has previously been
shown to suppress growth of SAOS-2 cells in an E2F-depen-
dent manner (22). IE1-72 could not alleviate growth suppres-
sion of SAOS-2 cells by overexpression of the N385 mutant of
p107. However, overexpression of the L19 mutant of p107,
which has a deletion of the region (aa 781 to 1068) that binds
to E2F4 and represses E2F4 transcription activity, led to IE1-72
alleviation of growth suppression (22). These results suggest
that alleviation of p107-mediated growth suppression by
IE1-72 may involve an E2F-dependent pathway as well as the
cyclin E/cdk2 pathway. These data further support the notion
that p107 regulates cell cycle progression by at least two dis-
tinct mechanisms: (i) inhibition of E2F transcription factor,
and (ii) interaction with cyclin/cdk through a second domain to
inactivate cyclin E/cdk kinase activity.
A critical question to be asked is, if the interaction between
IE1-72 and the p107-E2F complex did not result in the disso-
ciation of E2F from p107 (22), why did the expression of
IE1-72 alleviate the repression of the p107-mediated E2F-
responsive promoter? There are two possible mechanisms: (i)
IE1-72 interacts with p107-E2F to form a positive preinitiation
complex to up-regulate the E2F-responsive promoter, or (ii)
IE1-72 interacts with p107-E2F and results in the activation of
cyclin/cdk2 kinase activity which, in turn, phosphorylates the
pocket proteins and subsequently activates E2F transcriptional
activity. A recent study by Calbo et al. (5) demonstrated that
the phosphorylation of pocket proteins by G1 cyclin/cdk regu-
lated their interaction with E2Fs and the expression of genes
controlled by these transcription factors. They found that the
activation of cyclin E/cdk2 activity in the absence of D-type
cyclin/cdk activity was sufficient to induce E2F4 activation and
promote the expression of E2F-dependent genes. Their find-
ings strongly support the second notion described above.
Data presented in this communication suggest that the
IE2-71 interaction with p107 modulates cyclin E/cdk2 activity
(Fig. 1 to 3). The critical experimental result shown in Fig. 10
suggests that the binding of IE1-72 to p107 displaces cyclin
E/cdk2 from p107. These results support a model in which
IE1-72 binds to p107 and releases cyclin E/cdk2 (Fig. 11). This
release results in activation of the cyclin E/cdk2 kinase, which
is critical in cell cycle progression. IE1-72 appears to compete
with cyclin E/cdk2 for p107 binding, as the alleviation of p107
inhibition of cyclin E/cdk2 kinase activity increased with
IE1-72 protein expression (Fig. 3). We, therefore, speculate
that IE1-72 binds to p107 with higher affinity than cyclin
E/cdk2 does. However, further binding studies are required to
confirm this suspicion.
In mapping the domains of IE1-72 that interact with p107,
we previously demonstrated that exons 2 and 3 of IE1-72 are
required for binding to p107. Because exons 2 and 3 are shared
between IE1-72 and IE2-86, we hypothesized that the domain
of interaction on the IE1-72 and p107 proteins may extend into
exon 4, a region unique to IE1-72, to gain a correct protein
conformation for this interaction. In this report, we show that
a point mutation of the loop structure of the HLHTH region of
exon 3 prevents binding of the mutated IE1-72 to p107. In
addition, a point mutation of the LZ-2 region of exon 4 also
abolished binding to p107. These results suggest that the loop
structure of HLHTH and LZ-2 of IE1-72 work together to
form a specific conformation necessary for the interaction of
FIG. 11. Model of the activation of cyclinE/cdk2 kinase activity by
the overexpression of HCMV IE1-72.
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IE1-72 with p107. Results of the interaction study, as demon-
strated by co-IP and immunoblotting, were further confirmed
by biochemical analysis of cyclin/cdk kinase activity using his-
tone H1 as substrate (Fig. 5 and 6). Interestingly, IE2-86, which
contains exon 5 instead of exon 4, did not interact with p107.
In this study, we further demonstrated that deletion of aa 1
to 175 of the p107 sequence abolished the p107 interaction
with IE1-72 (Fig. 8). In addition, this mutated protein was not
able to inhibit cyclin E/cdk2 kinase activity (Fig. 9B, lane 3).
Thus, the aa 1 to 175 fragment at the N terminus of p107 is
required for binding to both IE1-71 and cyclin E/cdk2. This
experimental result is in agreement with the results obtained
by Woo et al. that showed aa 1 to 110 of p107 play an impor-
tant role in regulating cell cycle progression by inhibiting cyclin
E/cdk2 kinase activity (40).
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